[Myasthenia caused by D-penicillamine in rheumatoid arthritis]. 1994

A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
November 1977, Annals of internal medicine,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
January 1979, The Journal of rheumatology,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
January 1977, Proceedings of the Royal Society of Medicine,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
January 1979, Scandinavian journal of rheumatology. Supplement,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
September 1986, Southern medical journal,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
March 1996, Atencion primaria,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
January 1981, La Revue de medecine interne,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
April 1979, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
June 1991, Ryumachi. [Rheumatism],
A Héraud, and C Dromer, and E Fatout, and B Fournié, and A Fournié
January 1987, Terapevticheskii arkhiv,
Copied contents to your clipboard!